CytoDyn
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1111 Main St Ste 660, Vancouver, Washing...Phone Number
(360) 980-8524Website
www.cytodyn.comRevenue
-Stock Symbol
CYDYIndustry
About CytoDyn
CytoDyn Inc. is a U.S.-based, publicly traded clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, particularly in oncology and immunology. Founded in 2002 and headquartered in Vancouver, Washington, the company operates within the healthcare and biotechnology sector. The companys core focus is the development of leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptora key regulator of immune function involved in cancer progression, inflammation, and certain infectious diseases. Leronlimab is being studied as a potential treatment across multiple indications, with a strong emphasis on solid-tumor oncology, including metastatic colorectal cancer and triple-negative breast cancer.Explore more
SIC Code 28,283NAICS Code 54,541Ticker OTC: CYDYShow moreCytoDyn Org Chart
Compare Similar Companies to CytoDyn
Compare insights from companies similar to CytoDyn, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CytoDyn Tech Stack
A closer look at the technologies used by CytoDyn
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CytoDyn
Sign Up For FreeTo access detailed company insights
CytoDyn Inc. is a U.S.-based, publicly traded clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, particularly in oncology and immunology. Founded in 2002 and headquartered in Vancouver, Washington, the company operates within the healthcare and biotechnology sector. The companys core focus is the d... Read More

